Inhibitor Research Hub

Archives

  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • Epalrestat: Mechanistic Insights and Research Utility as ...

    2026-01-19

    Epalrestat is a high-purity aldose reductase inhibitor that offers targeted inhibition of the polyol pathway and direct KEAP1/Nrf2 pathway activation. Its validated neuroprotective and antidiabetic properties enable advanced research in diabetic complication and neurodegenerative disease models. APExBIO delivers Epalrestat with stringent quality control and workflow-ready formulation.

406 records 28/28 page Previous First page 上5页 262728